We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+130.68%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$355M
AUM Growth
+$103M
(+41%)
Cap. Flow
+$181M
Cap. Flow
% of AUM
51.07%
Top 10 Holdings %
Top 10 Hldgs %
59.98%
Holding
61
New
22
Increased
9
Reduced
5
Closed
10
Avg Time Held Equity + Options
2.6
quarters
Top 10 Avg Time Held Equity + Options
1.2
quarters
Top 20 Avg Time Held Equity + Options
1.9
quarters
Avg Time Held Equity only
2.6
quarters
Top 10 Avg Time Held Equity only
1.3
quarters
Top 20 Avg Time Held Equity only
1.9
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Icon
ICLR
|
+$45.7M |
| 2 |
Cigna
CI
|
+$22.8M |
| 3 |
Q32 Bio
QTTB
|
+$22M |
| 4 |
Sanofi
SNY
|
+$19.7M |
| 5 |
Maximus
MMS
|
+$18.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$24.3M |
| 2 |
Labcorp
LH
|
+$13.8M |
| 3 |
Kenvue
KVUE
|
+$11M |
| 4 |
Biodesix
BDSX
|
+$7.72M |
| 5 |
Relay Therapeutics
RLAY
|
+$6.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.96% |
| 2 | Industrials | 8.01% |
| 3 | Miscellaneous | 0.03% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Icon
ICLR
$12.7B
| $41M | 11.54% |
+195,500
| New | +$45.7M |
2024 Q4
0 quarters
|
|
|
2
Maximus
MMS
$3.04B
| $28.5M | 8.01% |
381,423
+226,281
| +146% | +$18.5M |
2024 Q3
1 quarter
|
|
|
3
Cigna
CI
$74.7B
| $27.1M | 7.61% |
98,003
+71,500
| +270% | +$22.8M |
2020 Q3
17 quarters
|
|
|
4
Labcorp
LH
$25.4B
| $26M | 7.31% |
113,293
-60,000
| -35% | -$13.8M |
2023 Q2
6 quarters
|
|
|
5
Sanofi
SNY
$93.7B
| $18.7M | 5.25% |
+387,000
| New | +$19.7M |
2024 Q4
0 quarters
|
|
6
Zimmer Biomet
ZBH
$17.6B
| $18.5M | 5.2% |
174,811
+47,300
| +37% | +$5.08M |
2023 Q3
5 quarters
|
|
7
Bright Minds Biosciences
DRUG
$507M
| $16.3M | 4.58% |
+451,793
| New | +$15.9M |
2024 Q4
0 quarters
|
|
8
Anteris Technologies
AVR
$629M
| $13.2M | 3.72% |
+2,370,000
| New | +$13.3M |
2024 Q4
0 quarters
|
|
9
Annexon
ANNX
$726M
| $12.1M | 3.42% |
2,367,007
+933,852
| +65% | +$5.75M |
2024 Q3
1 quarter
|
|
10
Teleflex
TFX
$5.27B
| $11.9M | 3.34% |
66,772
+27,500
| +70% | +$5.65M |
2023 Q3
5 quarters
|
|
11
Viatris
VTRS
$19.8B
| $9.09M | 2.56% |
+730,000
| New | +$8.97M |
2024 Q4
0 quarters
|
|
12
Organon & Co
OGN
$3.62B
| $9.05M | 2.55% |
+606,410
| New | +$9.88M |
2024 Q4
0 quarters
|
|
13
DELISTED
Ventyx Biosciences
VTYX
| $8.86M | 2.49% |
4,046,797
+2,074,849
| +105% | +$4.7M |
2024 Q1
3 quarters
|
|
14
ANI Pharmaceuticals
ANIP
$1.63B
| $8.85M | 2.49% |
+160,051
| New | +$9.19M |
2024 Q4
0 quarters
|
|
15
Embecta
EMBC
$351M
| $8.79M | 2.47% |
+425,574
| New | +$6.97M |
2024 Q4
0 quarters
|
|
16
Vir Biotechnology
VIR
$1.8B
| $7.74M | 2.18% |
+1,054,651
| New | +$8.32M |
2024 Q4
0 quarters
|
|
17
DELISTED
Vaxart
VXRT
| $7.62M | 2.15% |
11,515,315
-2,092,929
| -15% | -$1.45M |
2024 Q2
2 quarters
|
|
18
Protara Therapeutics
TARA
$155M
| $7.59M | 2.14% |
+1,437,500
| New | +$4.64M |
2024 Q4
0 quarters
|
|
19
DELISTED
CARGO Therapeutics
CRGX
| $6.82M | 1.92% |
473,292
+299,432
| +172% | +$5.43M |
2024 Q3
1 quarter
|
|
20
Neumora Therapeutics
NMRA
$69.6M
| $6.74M | 1.9% |
+636,300
| New | +$7.63M |
2024 Q4
0 quarters
|
|
21
Septerna Inc
SEPN
$1.7B
| $6.22M | 1.75% |
+271,687
| New | +$6.42M |
2024 Q4
0 quarters
|
|
22
ProQR Therapeutics
PRQR
$209M
| $5.44M | 1.53% |
+2,054,593
| New | +$6.52M |
2024 Q4
0 quarters
|
|
23
PMV Pharmaceuticals
PMVP
$72.2M
| $5.39M | 1.52% |
3,572,167
+357,928
| +11% | +$567K |
2024 Q2
2 quarters
|
|
24
Disc Medicine
IRON
$2.17B
| $4.66M | 1.31% |
73,511
-114,430
| -61% | -$6.62M |
2024 Q2
2 quarters
|
|
25
DELISTED
Astria Therapeutics
ATXS
| $4.51M | 1.27% |
504,887
| – | – |
2024 Q1
3 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q4 2024 Portfolio in Review
As of Q4 2024, Sio Capital Management held 61 positions worth $355M, up 41% from $252M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Sio Capital Management deployed $181M of net new capital in Q4 2024, opening 22 new positions and adding to 9 existing holdings. Its largest new stake was Icon: 195,500 shares worth $41M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Industrials and Miscellaneous.
On the sell side, the largest reduction was Labcorp, an estimated $13.8M trimmed.
- Sio Capital Management's largest Q4 2024 buy was Icon: 195,500 shares worth $41M.
- Sio Capital Management added most to Cigna in Q4 2024, an estimated $22.8M increase.
- Sio Capital Management's biggest Q4 2024 reduction was Labcorp, cutting an estimated $13.8M.
- Sio Capital Management fully exited Teva Pharmaceutical Industries Limited in Q4 2024, selling an estimated $24.3M.
- Sio Capital Management's ten largest holdings make up 60% of its $355M portfolio in Q4 2024.
- Sio Capital Management opened 22 new positions and closed 10 in Q4 2024.
- Sio Capital Management's portfolio value rose 41% quarter-over-quarter to $355M.
Based on Sio Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.